Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial

OBJECTIVE: This study investigated the treatment response and cognitive enhancement effects of buspirone augmentation of escitalopram in patients with major depressive disorder (MDD), according to atypical feature subtypes of MDD. METHODS: An 8 week, randomized, parallel-controlled, open-label study...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Cheolmin, Ko, Young-Hoon, Shim, Se-Hoon, Kim, Ji Sun, Na, Kyoung-Sae, Hahn, Sang-Woo, Lee, Seung-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neuropsychiatric Association 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449841/
https://www.ncbi.nlm.nih.gov/pubmed/32750760
http://dx.doi.org/10.30773/pi.2020.0017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449841/
https://www.ncbi.nlm.nih.gov/pubmed/32750760
http://dx.doi.org/10.30773/pi.2020.0017

Ejemplares similares